Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy ...

US manufacturers are increasingly nervous about President Trump’s tariffs. They’re already disrupting supply chains, and the ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists, medicinal chemists, ...

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain ...